businessbriefs
SubjectsAll subjects on briefs.cloud →
Saved
Companies

Daiichi Sankyo

2005

A merger-born giant that bought its way into oncology — but still answers to US prosecutors for kickbacks.

Worth your time?3.5/5Yes.Study the whole thing.What works, what does not, who it is for ↓
10:49in productionCh. 1 · The Merger/ 10:49 · ceiling 15 min
6 chapters · 10:49Ceiling 15:00

The brief is written and checked. The video joins this page when it is cut.6 chapters · 1 min read · 10:49 planned

Read the brief

Daiichi Sankyo is a post-merger pharmaceutical entity whose scale derives from consolidation — not innovation velocity. Its revenue is large, its global reach documented, but its growth levers are acquisitions and inherited assets. Its 2015 $39 million kickback settlement signals real regulatory exposure — not just theoretical compliance risk.

CompaniesPhotographyMedicineGlobalisationPhotography across the network →
Chapters & takeaways6
  1. 0:59
    The Merger

    Daiichi Sankyo did not grow organically — it was created in 2005 by merging two century-old Japanese firms.

  2. 2:16
    Scale and Standing

    It is Japan’s second-largest pharma firm and holds formal status in Europe and global industry bodies.

  3. 3:13
    How It Entered the US

    Revenue is reported at scale, but its US operations and commercial expansion began only in 2006 — via acquisition, not launch.

  4. 4:27
    Legacy Assets

    Its lineage includes foundational science — adrenaline isolation — and early global moves like the 1990 Munich acquisition.

  5. 5:50
    First Acquisition

    Its first US move was buying Zepharma — an OTC unit — not a novel drug or platform.

  6. 7:14
    Time Between Birth and Scale

    The 2005 merger set the stage, but the 2022 revenue figure reflects 17 years of consolidation — not the merger’s immediate output.

3 more chaptersFewer chapters
Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • merger execution
  • international institutional alignment (EFPIA/IFPMA)
  • acquisition sequencing in oncology
What does not
  • claim profitability
  • disclose R&D spend
  • state number of employees
  • identify key products or patents beyond adrenaline
Study it if
  • analysts tracking pharma M&A
  • regulatory watchers
  • Japan-based industrial historians
Skip it if
  • startups seeking innovation playbooks
  • investors assessing unit economics
Who should study it, and who should skipHide who it is for
The written brief1 min read

What the company or idea is

Daiichi Sankyo is a global pharmaceutical company formed in 2005 by merging two century-old Japanese firms: Sankyo Company, Limited and Daiichi Pharmaceutical Company, Limited.

How it actually makes money

Daiichi Sankyo makes money from selling pharmaceuticals globally, with JPY 1,278 billion in revenue in 2022.

What works

Its merger created Japan’s second-largest pharmaceutical company. Its international presence is verified via subsidiaries and membership in EFPIA and IFPMA. Its US entry in 2006 and subsequent oncology-focused acquisitions signal deliberate geographic and therapeutic repositioning.

What does not

It does not operate in the US as of 2005; its US subsidiary began in 2006. It does not claim or demonstrate profitability, margins, or R&D spend — only revenue and acquisition activity.

What to take from it

The gap between its self-presentation as a global innovator and its documented reliance on acquisitions (Zepharma, U3 Pharma, Plexxikon, Ambit Biosciences) and legacy assets (e.g., Luitpold-Werk, acquired in 1990 by Sankyo) reveals a strategy built more on consolidation than organic pipeline creation.

Is it worth your time

Yes — as a case study in post-merger portfolio expansion through targeted acquisitions and regulatory risk exposure in the US market.

Same desk · Companies4 of 325
11:20
Novartis1996Novartis is a Swiss multinational pharmaceutical corporation formed in 1996 by the merger of Ciba-Geigy and Sandoz. It operates as a publicly traded holding company with two main divisions — Innovative Medicines and Sandoz — and manufactures numerous branded drugs including clozapine, valsartan, imatinib mesylate, and cyclosporine. The merger combined the pharmaceutical and agrochemical divisions of the predecessor firms into an independent entity, and the company has since undergone extensive restructuring, acquisitions, divestitures, and spin-offs — including Alcon (spun off in 2019) and Sandoz (spun off in October 2023).
11:29
Sun Pharma1983Sun Pharma is a vertically distributed generic drug manufacturer whose scale is real, verifiable, and geographically dispersed — but whose economics, margins, and strategic vulnerabilities remain undocumented in the source material.
10:10
Roche1896Roche is a Swiss multinational holding healthcare company founded in 1896, headquartered in Basel, operating through Pharmaceuticals and Diagnostics divisions. It is the fifth-largest pharmaceutical company by revenue and the global leader in cancer treatments. It owns Genentech, Chugai Pharmaceuticals, Ventana, and Foundation Medicine as subsidiaries. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. In 2023, it ranked 76th in the Forbes Global 2000.
10:34
Novo Nordisk1923Novo Nordisk is a Danish multinational pharmaceutical company, founded in 1989 through the merger of two 1920s-origin insulin firms. It manufactures and markets pharmaceutical products and services, primarily for diabetes and obesity. Its first major device innovation was the Novopen insulin pen, launched in 1985. The 1989 merger made it the world’s largest insulin producer. Its headquarters are in Bagsværd.
Up next in Business

De Beers

Cecil Rhodes · 1888 · 10:51

De Beers wasn’t a diamond company — it was a scarcity engine.

Next brief →Back to Companies
10:51